
Mukul Minocha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11302425/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. The Lancet Gastroenterology and Hepatology, 2018, 3, 671-680.	8.1	126
2	Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. International Journal of Pharmaceutics, 2012, 434, 306-314.	5.2	74
3	Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. International Journal of Pharmaceutics, 2012, 436, 127-134.	5.2	60
4	Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography–tandem mass spectrometry (LC/MS–MS). Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 901, 85-92.	2.3	37
5	Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. Drug Metabolism and Drug Interactions, 2014, 29, 179-190.	0.3	30
6	Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. Drug Metabolism and Drug Interactions, 2014, 29, 249-259.	0.3	27
7	Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials. Clinical Pharmacokinetics, 2019, 58, 375-387.	3.5	25
8	Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials. Clinical Pharmacokinetics, 2019, 58, 1309-1321.	3.5	25
9	Effect of short term and chronic administration of Sutherlandia frutescens on pharmacokinetics of nevirapine in rats. International Journal of Pharmaceutics, 2011, 413, 44-50.	5.2	21
10	Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials. Clinical Pharmacokinetics, 2016, 55, 121-130.	3.5	9
11	Models of Variability and Circadian Rhythm in Heart Rate, Blood Pressure, and <scp>QT</scp> Interval for Healthy Subjects Who Received Placebo in Phase I Trials. Clinical and Translational Science, 2019, 12, 470-480.	3.1	8
12	Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. Clinical Pharmacokinetics, 2018, 57, 1185-1198.	3.5	7
13	Drug Development and Potential Regulatory Paths for Insulin Biosimilars. Journal of Diabetes Science and Technology, 2014, 8, 14-19.	2.2	6
14	Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus. Clinical Pharmacokinetics, 2020, 59, 335-347.	3.5	5